AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

30.06.18	AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge (Reuters)
29.06.18	Biotech Stocks Facing FDA Decision In July (RTTNews)
26.06.18	AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico (RTTNews)
19.06.18	8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities" (PR Newswire)
15.06.18	AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd... (PR Newswire)
15.06.18	AbbVie Declares Quarterly Dividend (PR Newswire)
13.06.18	AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) (PR Newswire)
08.06.18	AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma... (PR Newswire)
05.06.18	Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis (PR Newswire)
05.06.18	Arjo strengthens position within Long-Term Care in North America (PR Newswire)
04.06.18	AbbVie Announces Final Results of Tender Offer (PR Newswire)
03.06.18	Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) (PR Newswire)
01.06.18	Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone (PR Newswire)
31.05.18	StarfishETL Recognized for IT Management Software Excellence by FinancesOnline Directory (PR Newswire)
31.05.18	AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European... (PR Newswire)
30.05.18	AbbVie Announces Preliminary Results of Tender Offer (PR Newswire)
29.05.18	AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference (PR Newswire)
24.05.18	AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS (RTTNews)
24.05.18	IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint (PR Newswire)
22.05.18	AbbVie to Present at the Jefferies 2018 Global Healthcare Conference (PR Newswire)
16.05.18	AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting (PR Newswire)
13.05.18	Apon Wellbeing Ltd. wins MetLife Foundation Financial Innovation Competition powered by Verb, secures $50,000 Grant (PR Newswire)
08.05.18	AbbVie to Present at the UBS Global Healthcare Conference (PR Newswire)
02.05.18	AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference (PR Newswire)
01.05.18	AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis (PR Newswire)
01.05.18	AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock (PR Newswire)
30.04.18	AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology (PR Newswire)
27.04.18	AbbVie Presents New Investigational Data For Elagolix (RTTNews)
26.04.18	AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative (Moodys)
26.04.18	Umworbener Pharmakonzern Shire startet gesund ins Jahr (AWP) Der irische Pharmakonzern Shire zeigt sich vor der womöglich anstehenden Übernahme durch den japanischen Rivalen Takeda in starker Verfassung.» mehr
26.04.18	AbbVie Reports First-Quarter 2018 Financial Results (PR Newswire)
25.04.18	AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis (PR Newswire)
25.04.18	AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients (PR Newswire)
24.04.18	Modern Miracles: America's 10 Best-Selling Drugs (RTTNews)
19.04.18	Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising (Moodys)
18.04.18	AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference (PR Newswire)
11.04.18	AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten